Contact us
If you have a question or need a quotation for your project using one of our services, please just fill out the Inquiry Form on the "Contacts" page, and we will do our best to respond to your inquiry within 24 hours.
A free online tool for protein cleavage sites prediction with a chosen enzyme.
Calculate monoisotopic and average mass of a custom peptide or peptides predicted from a protein.
The cleavage specificities of selected enzymes.
A comprehensive and freely accessible resource of protein sequence and functional information.
Mass spectrum simulation tool for peptide/protein sequences. The number of charge can be custom defined.
An online tool predicts m/z values for SMS ions generated from selected fragmentation methods such as CID, ECD, or ETD. The ion type and maximum number of charge can be pre-defined.
PDB provides the most complete collection of information about the 3D structures of proteins, protein complexes and other biomolecules.
Useful links
Neutralizing Antibody
The outbreak of infectious diseases (e.g. COVID-19, Influenza, Ebola, Dengue, Zika, SARS, and MERS) remains a major threat for public health and requires effective therapeutics. Because of their superior therapeutic properties, neutralizing antibodies (nAbs) hold a great promise for a cure and prevention of these viral diseases. Unlike a vaccine which takes a long time to develop and can only be used as a prevention method by giving to healthy people, a neutralizing antibody (nAb) can block the viral entry process and help the infected individuals to clear the virus. In the case of 2019-nCov (SARS-Cov-2) coronavirus, a key step of the infection is that the receptor binding domain (RBD) of viral Spike protein attaches to ACE2 receptor on the surface of the host cell. Therefore, RBD has been employed as an effective target for developing neutralizing antibody drugs against COVID-19.
The Spike protein RBD has also been a hot target for developing neutralizing antibodies against SARS, a similar coronavirus disease as COVID-19. However, because of the amino acid mutations occurred in RBD of the new coronavirus SARS-Cov-2 (2019-nCov), most of the antibodies developed effective for SARS are no longer effective for COVID-19. In this regard, when looking for antibody drugs against coronaviruses such as SARS-Cov-2, it would be ideal to develop a broadly neutralizing antibody (bnAb) that can treat not only COVID-19, but also its mutant escapes and other potential coronaviruses in the future. Developing a bnAb is only possible when it binds to a broadly neutralizing epitope (cross-reactive epitope) on the target antigen. This can be achieved by screening the lead antibody candidates through TASTE, a tailored antibody epitope mapping platform we designed specifically for bnAb development for COVID-19 and other viral diseases.
Another interesting approach similar to bnAb is to use a combination of two or more monoclonal antibodies (mAb cocktail therapy) to generate synergistic effect and avoid virus mutant escapes. This approach has been successfully applied in the development of the drug REGN-EB3 for Ebola. Since the epitopes of the antibodies in the cocktail cannot overlap so that they don't compete with each other for binding, they need to be carefully characterized. NovoAb’s proprietary FineMapping platform offers a fast and cost-effective solution for antibody epitope mapping with up to single-residue resolution, and we believe our extensive experience in neutralizing antibody development for Influenza, SARS-Cov and Zika can help with your bnAb project. Contact us for free consultation.
